On July 23, 2020, CGD Senior Fellow Prashant Yadav appeared before the House Ways and Means Subcommittee on Trade at a hearing titled “Trade, Manufacturing, and Critical Supply Chains: Lessons From COVID-19.” Yadav’s testimony noted the vulnerabilities in supply chains for medical products clearly exposed by the COVID-19 pandemic and outlined key considerations for US policy toward medical supply chains moving forward.
Community health workers (CHWs) are often the first point of care for vulnerable and underserved populations in low- and middle-income countries, but do they have the PPE they need to do their jobs?
Diagnostic testing is at the center of the policy debate around COVID-19 interventions in India. As of June 1, 2020, India had conducted approximately 3.8 million tests since it began testing in February, but many experts have noted that testing capacity is still drastically insufficient for the needs of the population.
COVID-19 and Oxygen: Selecting Supply Options in LMICs that Balance Immediate Needs with Long-Term Cost-Effectiveness
Much of the policy debate regarding COVID-19 medical equipment focuses on the question of which form of patient respiratory support is effective in low-resources settings. However, irrespective of the specific form of respiratory support used, the long-term and cost-effective functioning of all forms of oxygen therapy requires an appropriate system to supply oxygen to hospitals.
Delivering on the Promise of “Equitable Access” to Epidemic Vaccines and Treatments: the Need for Norms, Processes, and Evidence to Guide Supply and Allocation
While there has been much interest and investment in developing epidemic vaccines and medicines to combat emerging infectious disease threats, there has been less attention to how we will manage and allocate the global supply of efficacious vaccines and treatments once we have them. The launch of the Access to COVID-19 Tools (ACT) Accelerator marks an unprecedented commitment to global collaboration to ensure rapid and equitable access to medical countermeasures for COVID-19, such as vaccines and treatments.
New technology, better use of data, and entrepreneurial passion in improving distribution channels is reaching a critical mass with the potential to drive extraordinary improvements in availability, affordability, and quality of health products. Global health institutions can play a significant role in further boosting the overall innovation ecosystem for health products distribution. However, most distribution system innovators are missing from global discussions around UHC and access to medicines.
Donors play a significant role in funding medicines and other commodities in global health. Of the approximately US $28.2 billion spent by donors in 2010, approximately 40% went towards medicines, vaccines and other health commodities, mainly in sub-Saharan Africa. The efficiency of this spend is therefore of great concern, given the large variability in supply chain costs.
Countering Drug Resistance in the Developing World: An Assessment of Incentives across the Value Chain and Recommendations for Policy Interventions - Working Paper 183
In this working paper, commissioned as part of CGD's Drug Resistance Working Group, Prashant Yadav analyzes how changes in supply-chain business practices could help fix the misaligned incentives that hinder worldwide access to high-quality medical goods.